About Cutaneous Lymphoma

Allos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN (pralatrexate) for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Wed, 09/02/2009

 

Click here to read more on this news.